Frontage Laboratories Expands Clinical Capabilities
Frontage Laboratories, Inc. (NASDAQ: FRTX), a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), is pleased to announce an exciting expansion of its early phase clinical research capabilities. This strategic move significantly strengthens the company's ability to support its pharmaceutical and biotech partners with high-quality and efficient clinical development solutions.
Growth of US and China Operations
With the expansion, Frontage is broadening its operational footprint across the United States and China. The efforts aim to enhance the company’s clinical trial services, enabling quicker and more reliable research experiences. Frontage's operations in the United States are centered around a modern 160-bed clinical unit in Secaucus, New Jersey. This state-of-the-art facility is specifically designed to manage large-scale Phase I and Bioequivalence studies, along with radiolabeled human AME research.
Advanced Radiation Research Capabilities
To bolster its capabilities, Frontage has expanded its C14-hAME services through a dedicated unit staffed by licensed radiation experts. The unit is complemented by an onsite nuclear pharmacy that supports sterile and non-sterile radiolabeled compounding. This enhancement allows Frontage to conduct combined hAME and Absolute Bioavailability studies in alignment with recent FDA guidance, ensuring the highest standards of research quality.
Oncology Phase I Trials and Collaborative Efforts
Recognizing the increasing demand for oncology research, Frontage is broadening its focus into Oncology Phase I trials. Collaborations with regional hospitals and clinical networks will enable the company to carry out patient-centric research across significant cancer-related indications. This initiative reflects Frontage’s commitment to advancing medical research and improving patient outcomes.
Addressing Patent Expirations with Strategic Solutions
The pharmaceutical industry is approaching a crucial point with a wave of patent expirations, and Frontage is strategically positioned to handle complex and high-volume Bioequivalence programs. With multiple clinical units throughout the United States, the company is equipped to tackle the challenges presented by these expirations. Furthermore, the collaboration with Frontage China facilitates the execution of flexible Multi-Regional Clinical Trials (MRCT), effectively supporting global program timelines.
“One-Stop Shop” Model for Integrated Services
One of the hallmarks of Frontage's offerings is its innovative “One-Stop Shop” model. This unique approach combines various services including Bioanalytical & Central Lab services, Drug Metabolism and Pharmacokinetics (DMPK), and Chemistry, Manufacturing and Controls (CMC). By integrating these services under one roof, Frontage aims to reduce the number of handoffs between service providers, thereby accelerating timelines and lowering overall study costs for its clients.
Client-Centric Approach and Global Reach
Frontage Laboratories takes pride in its client-centric methodology, offering unmatched support throughout the drug development process. Having operated for over 25 years in the industry, the company has successfully aided numerous pharmaceutical and biotech clients in achieving regulatory approvals across various global markets, including the United States, Canada, Europe, and Asia. This extensive international experience has positioned Frontage as a trusted partner in the journey from drug discovery to market.
Contact Information and Further Engagement
For those seeking further information about Frontage Laboratories, please feel free to reach out. This commitment to accessibility ensures that stakeholders can easily engage with the company for any inquiries regarding its services.
About Frontage
Frontage Laboratories, Inc. specializes in offering end-to-end integrated product development services, ranging from drug discovery and API synthesis to late-phase clinical trials and manufacturing processes. As a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), Frontage continues to adapt and evolve to meet the demands of clients across the pharmaceutical and biotech industries.
With 26 sites worldwide, Frontage maintains a pivotal role in assisting clients to successfully navigate regulatory landscapes, ensuring innovative therapies reach those in need.
Frequently Asked Questions
What is Frontage Laboratories, Inc.?
Frontage Laboratories, Inc. is a global CRDMO offering various integrated product development services for pharmaceutical and biotech companies.
Where is Frontage's main clinical unit located?
The primary clinical unit of Frontage is located in Secaucus, New Jersey, featuring a modern 160-bed facility.
What types of studies does Frontage conduct?
Frontage conducts Phase I clinical trials, Bioequivalence studies, and radiolabeled human AME research among others.
How does Frontage support oncology research?
Frontage is expanding into Oncology Phase I trials by collaborating with regional hospitals and clinical networks for patient-based research.
What is the “One-Stop Shop” model offered by Frontage?
Frontage's “One-Stop Shop” model integrates services to streamline the clinical trial process, reducing timelines and costs significantly for clients.
